AU2006337626B2 - [4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases. - Google Patents

[4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases. Download PDF

Info

Publication number
AU2006337626B2
AU2006337626B2 AU2006337626A AU2006337626A AU2006337626B2 AU 2006337626 B2 AU2006337626 B2 AU 2006337626B2 AU 2006337626 A AU2006337626 A AU 2006337626A AU 2006337626 A AU2006337626 A AU 2006337626A AU 2006337626 B2 AU2006337626 B2 AU 2006337626B2
Authority
AU
Australia
Prior art keywords
benzo
carboxylic acid
pyrimidin
mmol
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006337626A
Other languages
English (en)
Other versions
AU2006337626A1 (en
AU2006337626A8 (en
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Michael Enrico Richett
Chuan Shih
Q May Wang
Bo Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2006337626A1 publication Critical patent/AU2006337626A1/en
Publication of AU2006337626A8 publication Critical patent/AU2006337626A8/en
Application granted granted Critical
Publication of AU2006337626B2 publication Critical patent/AU2006337626B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006337626A 2005-11-18 2006-11-15 [4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases. Ceased AU2006337626B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
US60/738,097 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (3)

Publication Number Publication Date
AU2006337626A1 AU2006337626A1 (en) 2007-08-16
AU2006337626A8 AU2006337626A8 (en) 2008-06-19
AU2006337626B2 true AU2006337626B2 (en) 2012-03-22

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006337626A Ceased AU2006337626B2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases.

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51423B (sr) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. Benzoimidazol-2-il pirimidini i pirazini kao modulatori histaminskog h4 receptora
WO2008011557A2 (en) * 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
MX2009006635A (es) 2006-12-21 2009-06-30 Lilly Co Eli Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer.
AU2007334039B2 (en) 2006-12-21 2012-02-16 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer
BRPI0811433A2 (pt) 2007-05-16 2016-03-22 Lilly Co Eli compostos do tipo triazolil aminopirimidina
US8114872B2 (en) 2007-05-16 2012-02-14 Eli Lilly And Company Triazolyl aminopyrimidine compounds
PT2310012E (pt) 2008-06-30 2015-04-02 Janssen Pharmaceutica Nv Processo para a preparação de derivados de pirimidina substituída
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
MX2012012502A (es) 2010-04-27 2013-01-18 Hutchison Medipharma Ltd Compuestos pirimidinil indol.
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. ヘテロアリール化合物およびそれらの使用方法
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
EP3573964A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089913A1 (en) * 2003-04-11 2004-10-21 Novartis Ag Aminopyrimidine derivatives and their medical use
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089913A1 (en) * 2003-04-11 2004-10-21 Novartis Ag Aminopyrimidine derivatives and their medical use
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use

Also Published As

Publication number Publication date
ZA200803940B (en) 2009-09-30
CR9947A (es) 2008-11-28
BRPI0618245A2 (pt) 2011-08-23
EA014426B1 (ru) 2010-12-30
DK1989200T3 (da) 2009-11-09
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
AU2006337626A8 (en) 2008-06-19
JP2009516697A (ja) 2009-04-23
EP1989200B1 (en) 2009-07-29
PE20070833A1 (es) 2007-08-27
SI1989200T1 (sl) 2009-12-31
US7547691B2 (en) 2009-06-16
TNSN08227A1 (en) 2009-10-30
AR057911A1 (es) 2007-12-26
WO2007092095A2 (en) 2007-08-16
TW200800201A (en) 2008-01-01
DE602006008187D1 (de) 2009-09-10
US20080306082A1 (en) 2008-12-11
PT1989200E (pt) 2009-10-12
MA30053B1 (fr) 2008-12-01
PL1989200T3 (pl) 2009-12-31
WO2007092095A3 (en) 2007-11-08
NO20082594L (no) 2008-06-10
ECSP088456A (es) 2008-06-30
IL190489A0 (en) 2008-11-03
ATE437873T1 (de) 2009-08-15
EP1989200A2 (en) 2008-11-12
CN101309918A (zh) 2008-11-19
CN101309918B (zh) 2010-12-29
KR100990771B1 (ko) 2010-10-29
ES2329085T3 (es) 2009-11-20
KR20080059451A (ko) 2008-06-27
EA200801362A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
AU2006337626B2 (en) [4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases.
EP1686999B1 (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1615898B1 (en) 2-Aminopyrimidine derivatives and their medical use
US20090233928A1 (en) Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
NZ522188A (en) Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the NP Y5 receptor
AU2007242594A1 (en) Pyrimidine derivatives as PI3K inhibitors
KR20190013721A (ko) Tam 저해제로서의 피롤로트리아진 화합물
KR20140103996A (ko) Lrrk2 조절제로서 아미노피리미딘 유도체
JPH09504520A (ja) 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体
CN104582707B (zh) 三嗪化合物
CN102892761A (zh) 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂
MXPA01009871A (es) Aminopiridinas como inhibidores de la sorbitol deshidrogenasa.
CA2628283A1 (en) Bi-aryl meta-pyrimidine inhibitors of kinases
AU2008237715A1 (en) Pharmaceutical compounds
KR20110133056A (ko) 오로라 키나제 조절제 및 사용 방법
CN114105887B (zh) 一种氨基嘧啶衍生物及其制备方法和用途
AU2008254318B2 (en) Triazolyl aminopyrimidine compounds
CN101479277A (zh) 作为pi3k抑制剂的嘧啶衍生物
AU2011307220A1 (en) Phenylquinazoline derivatives
HK40109049A (en) Pyrrolotriazine compounds as tam inhibitors
HK1092723B (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 22, NO 19, PAGE(S) 2286 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME ELI LILLY AND COMPANY, APPLICATION NO.2006337626, UNDER INID (54) CORRECT THE TITLE TO READ [4-(BENZO [B] THIOPHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired